NFlection Therapeutics Seeking Adult Patients for Investigational Study on Cutaneous Neurofibromas (cNFs)
Author: NFlection Therapeutics
Published On: 10/12/2022
NFlection Therapeutics is currently recruiting adult patients for an investigational study of NFX-179 Topical Gel for reducing the appearance of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). NFX-179 is a topical, first-in-class, “soft” MEK inhibitor that is currently being evaluated in Phase 2 clinical trials.
Volunteers, aged 18 years and older, are wanted for a clinical research study using an investigational topical medication. Patients must have a clinical diagnosis of NF1 and must have 10 or more cutaneous neurofibromas on their skin, including 1-2 on their face. During this study, all participants are seen by a board-certified physician. There is no cost for study-related evaluations and qualified participants will be reimbursed for time and travel.
To learn more about this clinical trial and to be connected to available clinic sites, visit https://www.nflectionrx.com/.
Anyone considering participating in a clinical trial should discuss the matter with his or her physician. If you or a loved one is interested in participating in NF research, please read our clinical trials brochure to learn more about the clinical trial process and what that entails.